Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE1A | P54750 | 2/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 2/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.79 |
| ▸ | PDE6C | P51160 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | PDE2A | O00408 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.64 |
| ▸ | PDE6D | O43924 | 1/20 | 0.64 |
| ▸ | PDE8A | O60658 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174349 | 1.00 | PDE5A (1.00) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL31202656 | 0.93 | PDE5A (0.86) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL799 | 0.93 | PDE5A (0.86) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL6718781 | 0.92 | PDE5A (0.85) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL12462404 | 0.91 | PDE5A (0.84) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL1751 | 0.91 | PDE5A (0.83) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL3316795 | 0.90 | PDE5A (0.82) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL6719476 | 0.90 | PDE5A (0.81) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL1160 | 0.89 | PDE5A (0.80) | PDE5AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL735 | 0.88 | PDE5A (0.79) | PDE5AKMT2APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | disclosed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| CN-111116591-A | Method for preparing sildenafil citrate | 天津科伦药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | disclosed |
| US-9969744-B2 | Compounds for use in cognition improvement | FUNDACIÓN LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-05-15 | — | — | US | disclosed |
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-03 | — | — | US | disclosed |
| US-9663439-B2 | Aildenafil citrate crystal form O, preparation method and use thereof | HONG KONG GOLDEN WISDOM MEDICAL PRODUCTION LIMITED (HK) | 2017-05-30 | — | — | US | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | PDE5A 1/4885KMT2A 2669/4885PDE1A 31/4885 |
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | CHAT, NLN, GRIN2C | PDE5A 1677/4885KMT2A 1826/4885PDE1A 831/4885 |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | PDE5A 1/4885KMT2A 2669/4885PDE1A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.